Immuron Ltd — Regulatory Filings 2009

Aug 12, 2009

==> picture [193 x 42] intentionally omitted <==

==> picture [145 x 84] intentionally omitted <==

13 August 2009

The Manager The Company Announcement Office Australian Stock Exchange Sydney NSW

Dear Sir

Influenza Drug Development Program.

Immuron has entered into discussions with a top-25 global pharmaceutical company in respect of the potential joint development of Immuron’s influenza treatment and prevention product. As previously announced, we have achieved very positive results in our pre-clinical (animal) trials on our influenza product.

This is an important step in the evolution of Immuron as it scientifically and commercially progresses this new influenza product.

No further details can be released in respect of these discussions at this point of time however we will keep the market informed on the progress of our development program.

Immuron is continuing to attract interest in assisting with the scientific development and commercialisation of products from its pipeline.

Yours faithfully

==> picture [138 x 80] intentionally omitted <==

Professor Colin Chapman Executive Chairman